ArticleAnnals of neurology2013
Plasma apolipoprotein A1 as a biomarker for Parkinson disease.
Article in Annals of neurology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 1 synthesis or guideline pooled it, 138 citations in OpenAlex.
- Plasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson's disease patients.Movement disorders : official journal of the Movement Disorder Society · 2015Pooled it
- An acoustic-only multivariable diagnostic model for Parkinson's disease using bowel sound acoustic signatures.Journal of Parkinson's disease · 2026Article
- The APOA1-SNCA Axis as a Molecular Bridge Between CKD and Parkinson's Disease: A Systems Biology Model of Kidney-to-Brain Propagation via Exosomal Pathways.International journal of molecular sciences · 2026Article
- Unveiling the Proteomic Landscape of Extracellular Vesicles: Implications for Neurodegeneration and Neuroprotection.Journal of neurochemistry · 2026Review
- The quest for Parkinson's disease biomarkers: traditional and emerging multi-omics approaches.Molecular biology reports · 2025Review
- Apolipoprotein A (ApoA) in Neurological Disorders: Connections and Insights.International journal of molecular sciences · 2025Review
- Association of cholesterol and glycemic state biomarkers with phenotypic variation and Parkinson's disease progression: The Oxford Discovery cohort.Journal of Parkinson's disease · 2025Article
- The Significance of High-Density Lipoprotein-Derived Inflammatory Parameters in Atypical Parkinsonisms-Pilot Study.Journal of clinical medicine · 2025Article
- A Rapid and Modular Nanobody Assay for Plug-and-Play Antigen Detection.bioRxiv : the preprint server for biology · 2025Article
- Proteomic Analysis of Chronic Binge Alcohol-Induced Hippocampal and Anterior Cingulate Cortex Neuroadaptations in Simian Immunodeficiency Virus (SIV)-Infected Female Rhesus Macaques.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025Article
- Differential Expression of Fibrinogen Alpha and Its Potential Involvement in Osteoarthritis Pathogenesis.Molecular biotechnology · 2025Article
- Galantamine-Memantine Combination in the Treatment of Parkinson's Disease Dementia.Brain sciences · 2024Review
- Parkinson's Disease: Biomarkers for Diagnosis and Disease Progression.International journal of molecular sciences · 2024Review
- Lipoprotein Particles in Cerebrospinal Fluid.Arteriosclerosis, thrombosis, and vascular biology · 2024Review
- Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early Parkinson's disease.Acta neuropathologica · 2024Article
- Transcriptome-based biomarker prediction for Parkinson's disease using genome-scale metabolic modeling.Scientific reports · 2024Article
- Pros and cons for statins use and risk of Parkinson's disease: An updated perspective.Pharmacology research & perspectives · 2023Review
- Alternations of Lipoprotein Profiles in the Plasma as Biomarkers of Huntington's Disease.Cells · 2023Article
- Identification of a possible proteomic biomarker in Parkinson's disease: discovery and replication in blood, brain and cerebrospinal fluid.Brain communications · 2023Article
- Crosstalk between neurological, cardiovascular, and lifestyle disorders: insulin and lipoproteins in the lead role.Pharmacological reports : PR · 2022Review
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 1 country.
Funding
Abstract
objectiveTo identify plasma-based biomarkers for Parkinson disease (PD) risk.
methodsIn a discovery cohort of 152 PD patients, plasma levels of 96 proteins were measured by multiplex immunoassay; proteins associated with age at PD onset were identified by linear regression. Findings from discovery screening were then assessed in a second cohort of 187 PD patients, using a different technique. Finally, in a third cohort of at-risk, asymptomatic individuals enrolled in the Parkinson's Associated Risk Study (PARS, n = 134), plasma levels of the top candidate biomarker were measured, and dopamine transporter (DAT) imaging was performed, to evaluate the association of plasma protein levels with dopaminergic system integrity.
resultsOne of the best candidate protein biomarkers to emerge from discovery screening was apolipoprotein A1 (ApoA1; p = 0.001). Low levels of ApoA1 correlated with earlier PD onset, with a 26% decrease in risk of developing PD associated with each tertile increase in ApoA1 (Cox proportional hazards, p < 0.001, hazard ratio = 0.742). The association between plasma ApoA1 levels and age at PD onset was replicated in an independent cohort of PD patients (p < 0.001). Finally, in the PARS cohort of high-risk, asymptomatic subjects, lower plasma levels of ApoA1 were associated with greater putaminal DAT deficit (p = 0.037).
interpretationLower ApoA1 levels correlate with dopaminergic system vulnerability in symptomatic PD patients and in asymptomatic individuals with physiological reductions in dopamine transporter density consistent with prodromal PD. Plasma ApoA1 may be a new biomarker for PD risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.